Russell Investments Group’s Xeris Biopharma Holdings XERS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.49M Buy
440,731
+56,536
+15% +$361K ﹤0.01% 1733
2026
Q1
$2.23M Buy
384,195
+19,409
+5% +$129K ﹤0.01% 1827
2025
Q4
$2.86M Buy
364,786
+113,408
+45% +$893K ﹤0.01% 1666
2025
Q3
$2.05M Buy
251,378
+128,189
+104% +$852K ﹤0.01% 1840
2025
Q2
$575K Sell
123,189
-8,498
-6% -$38.9K ﹤0.01% 2281
2025
Q1
$723K Buy
131,687
+113,713
+633% +$459K ﹤0.01% 2165
2024
Q4
$60.9K Buy
17,974
+16,848
+1,496% +$54.2K ﹤0.01% 2781
2024
Q3
$3.21K Buy
1,126
+729
+184% +$1.87K ﹤0.01% 3302
2024
Q2
$893 Buy
397
+195
+97% +$393 ﹤0.01% 3443
2024
Q1
$446 Buy
+202
New +$523 ﹤0.01% 3220
2023
Q4
– Sell
-119
Closed -$221 – 3318
2023
Q3
$221 Buy
+119
New +$273 ﹤0.01% 3485
2021
Q3
– Sell
-77,815
Closed -$316K – 3232
2021
Q2
$316K Hold
77,815
– – ﹤0.01% 2763
2021
Q1
$350K Hold
77,815
– – ﹤0.01% 2661
2020
Q4
$382K Hold
77,815
– – ﹤0.01% 2535
2020
Q3
$461K Buy
+77,815
New +$311K ﹤0.01% 2430

Other funds holding XERS

Russell Investments Group's XERS Position: Q2 2026 in Review

Russell Investments Group increased its Xeris Biopharma Holdings (XERS) stake by 15% in Q2 2026, buying an estimated $361K and bringing the position to 440,731 shares worth $3.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1733.

Russell Investments Group first reported a position in XERS in Q3 2020 and has held it in 15 quarters since. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Russell Investments Group held 440,731 shares of Xeris Biopharma Holdings worth $3.49M as of Q2 2026.
  • Russell Investments Group bought 56,536 Xeris Biopharma Holdings shares in Q2 2026, an estimated $361K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #1733 holding.
  • Russell Investments Group first reported a position in Xeris Biopharma Holdings in Q3 2020 and has held it in 15 quarters since.
  • 240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.